A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
473
Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
Placebo to Rizatriptan, Oral Tablet
Pain Relief at 2 Hours During the First Migraine Attack Period
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) at baseline to grades 0 or 1 (no headache or mild) at 2 hours after initial dosing for the first migraine attack
Time frame: 2 hours
Pain Relief at 2 Hours During the Second Migraine Attack Period
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the second migraine attack
Time frame: 2 hours
Pain Relief at 2 Hours During the Third Migraine Attack Period
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the third migraine attack
Time frame: 2 hours
Pain Relief at 2 Hours During the Fourth Migraine Attack Period
Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the fourth migraine attack
Time frame: 2 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.